The CraniUS Plate, a Class II device from CraniUS, LLC, has received FDA 510(k) clearance via a Special submission, signaling its substantial equivalence for specific cranial applications.
CraniUS, LLC has secured 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its CraniUS Plate, a device intended for cranial reconstruction. The clearance, identified as K262874, was granted on September 11, 2026, categorizing the product as substantially equivalent under a Special 510(k) submission pathway.
The CraniUS Plate falls under Product Code GWO, aligning with regulation number 882.5320, which pertains to plates, screws, and staples for neurosurgical applications. The device is a Class II medical device, indicating a moderate level of regulatory control.
This clearance follows a Special 510(k) submission, a pathway typically used for modifications to a manufacturer’s own previously cleared device, or for a new device that does not raise new questions of safety and effectiveness, building upon an existing predicate device. Details regarding the specific predicate device were not disclosed in the public record.
Regulatory Pathway and Device Classification
The CraniUS Plate's clearance as a Class II device implies that general controls are insufficient to assure the safety and effectiveness of the device, and special controls are necessary. These special controls may include performance standards, post-market surveillance, patient registries, or guidelines for design and manufacturing. The Advisory Committee for this submission was Neurology, consistent with the device's intended use.
Implications for Cranial Reconstruction
The market for cranial reconstruction devices includes a variety of plates and mesh systems designed to repair defects in the skull, whether resulting from trauma, surgical procedures, or congenital conditions. The entry of the CraniUS Plate suggests an expansion of available options for surgeons, though specific design features, material composition, and clinical performance data beyond the regulatory finding of substantial equivalence have not been made public.
The FDA's 'substantially equivalent' determination means the device is as safe and effective as a legally marketed predicate device, without requiring new clinical trials for market entry.
As of this announcement, specific pricing, distribution channels, and detailed technical specifications for the CraniUS Plate have not been publicly disclosed by CraniUS, LLC. The company's strategy for market introduction and clinical adoption remains to be seen.
